{"id":"d2769944-bbb3-531e-a64a-5f0c47036afb","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:dpn24-metabolic-null","predicate":"no_detected_change_in_recorded_comparison","statement":"The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"c0aaa51a-179e-5abd-804c-17cba00ba597","mechanism_event_label":"The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"79196780-ce43-5024-94d5-b4a904e58755","slug":"human-dpn-hba1c-lipids","display_name":"Human DPN-trial HbA1c and lipid measurements","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c0aaa51a-179e-5abd-804c-17cba00ba597","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:dpn24-metabolic-null-event","event_type":"experimental_observation","label":"The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.","description":"### dpn24-metabolic-null\n\nThe 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.\nThis limits a claim that the composite benefit was demonstrated to result from improved systemic glycemic control.\nModel and exposure: Same randomized trial; supplementary Table 5 described in Results.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"ALCAR hydrochloride for 24 weeks","sequence_order":0,"notes":""},{"entity":{"id":"79196780-ce43-5024-94d5-b4a904e58755","slug":"human-dpn-hba1c-lipids","display_name":"Human DPN-trial HbA1c and lipid measurements","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"ALCAR hydrochloride for 24 weeks\", \"comparator\": \"Placebo\", \"endpoint\": \"The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Same randomized trial; supplementary Table 5 described in Results.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference dpn24-metabolic-null; This limits a claim that the composite benefit was demonstrated to result from improved systemic glycemic control.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"faff44f1-9ab9-579c-8bfd-5f423b914ae8","evidence_kind":"source_excerpt","locator":"Lines 531-537","start_line":531,"end_line":537,"excerpt":"### dpn24-metabolic-null\n\nThe 2024 neuropathy benefit did not coincide with significant HbA1c, total-cholesterol or triglyceride changes.\nThis limits a claim that the composite benefit was demonstrated to result from improved systemic glycemic control.\nModel and exposure: Same randomized trial; supplementary Table 5 described in Results.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38320260/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11043058/ | https://doi.org/10.2337/db23-0377 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Same randomized trial; supplementary Table 5 described in Results.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}